Clinical Trial Search

Primary: Overall Summary of Adverse Events — 71; 19; 4; 29 Participant

Primary: Change From Baseline in Brief Pain Inventory (BPI) Severity Score at Day 30 — 7.20; 3.83; 5.59; 5.49 Units on a scale

Primary: LDL Cholesterol — 116.34; 118.84 mg/dl

Primary: The Safety and Toxicity of ALT-801 in Patients With Progressive Metastatic Malignancies — 0; 2; 4 Events

Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Time t [AUC(0-t)] of Albendazole. — 54.82; 48.07 nanogram (ng).hr per milliliter (mL)

Primary: Number of Participants With a Positive Blood Culture for L. Reuteri — 0; 0 participants

Primary: Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 24 — 15.0; 31.9; 44.8; 38.7 Percentage of participants — p=<0.0001

Primary: Difference in Wrinkle Assessment Score, Between Pre-treatment and 12 Weeks Post-treatment. — 1.13 units on a scale

Primary: Change From Baseline in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Day 15 — 5.83; 6.16; 5.88; -0.77 log 10 IU/mL

Primary: Change in Weight — -6.0; -2.0 percentage of change in weight

Primary: The Primary Efficacy End Point is the Number of Patients With an Objective Response. — 39 Participants — p=0.05

Primary: Proportion of Patients With Moderate to Severe Hypopigmentation and Hyperpigmentation Assessed After Treatment — 0; 0 participants

Primary: Comparison of Th2 Cytokines (IL-13) Between Placebo and Probiotic Groups at Baseline (Beginning of Product Intake), 4 Weeks (Mid Period of Product Intake) and 8 Weeks…

Primary: 3 Scores on the Addiction Research Center Inventory (ARCI) — 7.6; 5.4; 5.2; 3.3 scores on a scale

Primary: BMD at Left Total Hip — 0.02 % change in BMD (gm/cm2) from baseline